| Literature DB >> 34970109 |
Ying Zhang1, Zhixiang Zhang1, Min Zhang1, Yin Cao1, Wenwei Yun1.
Abstract
Background and Purpose: Diabetic retinopathy (DR) is one of the common microvascular complications in diabetes. The total magnetic resonance imaging (MRI) burden of cerebral small vessel disease (CSVD) tends to be increased in diabetic patients and is a marker of microvascular disease; however, the relationship between DR and CSVD is unclear. This study aimed to explore the relationship between retinal microvascular abnormalities and the total MRI burden of CSVD in patients with type 2 diabetes.Entities:
Keywords: cerebral small vessel disease; diabetic retinopathy; retinal microvascular; retinal photography; type 2 diabetes
Year: 2021 PMID: 34970109 PMCID: PMC8712683 DOI: 10.3389/fnins.2021.727998
Source DB: PubMed Journal: Front Neurosci ISSN: 1662-453X Impact factor: 4.677
FIGURE 1A screenshot of the Image J interface.
FIGURE 2Fundus photographs showing features of a normal fundus and features of the various grades of diabetic retinopathy. (A) Photograph of a normal fundus. (B) Fundus image showing mild non-proliferative diabetic retinopathy with microaneurysms. (C) Fundus image showing moderate non-proliferative diabetic retinopathy with hemorrhages, hard exudates, and microaneurysms. (D) Fundus image showing severe non-proliferative diabetic retinopathy.
FIGURE 3MRI images from patients with different cerebral small vessel disease scores. Zero points: This patient was a 46-year-old man with no apparent lesions on MR images. One point: This patient was a 56-year-old man. Enlarged perivascular spaces (PVS) (grade 3) could be seen in the brain cortex on T2-weighted imaging. MR images showed no other abnormality. Two points: This patient was a 72-year-old woman. MRI demonstrated a lacune in the right basal ganglia, smooth halo-like lesions near the bilateral ventricles (Fazekas 2 for periventricular WMH), confluent white matter hyperintensities (Fazekas 2 for deep WMH) in the deep lobe and enlarged PVS (grade 1) in the bilateral basal ganglia. Susceptibility-weighted imaging showed no abnormality. Three points: This patient was a 69-year-old woman. MRI showed irregular white matter lesions in the lateral ventricles extending to the white matter (Fazekas 3 for periventricular WMH), large confluent areas of WMH (Fazekas 3 for deep WMH) in the center of the bilateral semioval and enlarged PVS (grade 3). Four points: This patient was a 77-year-old man. There were patchy, irregular white matter lesions extending to the white matter in the lateral ventricle (Fazekas 3 for periventricular WMH), fused WMH (Fazekas 3 for deep WMH), and 2 lacunes in the parietal lobe, enlarged PVS (grade 2) in the bilateral basal ganglia, and cerebral microbleeds at the level of the bilateral ventricles. All 4 MRI markers appeared in the images from this patient.
Clinical characteristics of the study population according to DR status (NDR, mild DR, or more than mild DR).
| Variables | NDR ( | Mild DR ( | More than mild DR ( | |
| Age, y; mean ± SD | 62.3 ± 8.6 | 65.5 ± 8.0 | 66.3 ± 8.2 | 0.030 |
| Male, n (%) | 44 (52.4) | 14 (51.9) | 16 (40.0) | 0.413 |
|
| ||||
| Smoking, n (%) | 22 (23.8) | 11 (40.7) | 9 (22.5) | 0.178 |
| Alcohol consumption, n (%) | 14 (16.7) | 6 (22.2) | 9 (22.5) | 0.675 |
| Hypertension, n (%) | 51 (60.7) | 18 (66.7) | 27 (67.5) | 0.714 |
| Duration of diabetes, years, median (IQR) | 10 (4, 15) | 12 (10, 20) | 19.5 (10, 21) | <0.001 |
| Previous stroke, n (%) | 14 (16.7) | 5 (18.5) | 9 (22.5) | 0.737 |
| Coronary heart disease, n (%) | 6 (7.1) | 2 (7.4) | 0 (0) | 0.218 |
| Carotid artery plaques, n (%) | 51 (60.7) | 19 (70.4) | 29 (72.5) | 0.367 |
| Systolic BP, mmHg, mean ± SD | 135 ± 18 | 129 ± 17 | 143 ± 21*[ | 0.009 |
| Diastolic BP, mmHg, mean ± SD | 78 ± 10 | 75 ± 12 | 78 ± 11 | 0.314 |
| BMI, kg/m2, mean ± SD | 24.16 ± 3.57 | 23.58 ± 2.92 | 23.88 ± 3.11 | 0.715 |
|
| ||||
| Fasting glucose, mmol//L, median (IQR) | 8.38 (6.62, 11.30) | 8.06 (6.29, 12.09) | 8.79 (6.89, 11.70) | 0.774 |
| HbA1c, %, median (IQR) | 8.40 (7.73, 10.50) | 8.40 (7.30, 10.50) | 8.45 (7.53, 9.95) | 0.880 |
| Total cholesterol, mmol//L, mean ± SD | 4.29 ± 1.02 | 4.60 ± 1.59 | 4.46 ± 1.34 | 0.492 |
| Triglycerides, mmol//L, mean ± SD | 1.86 ± 1.17 | 1.81 ± 1.41 | 1.70 ± 1.02 | 0.771 |
| LDL-C, mmol//L, mean ± SD | 2.42 ± 0.71 | 2.56 ± 0.90 | 2.55 ± 0.87 | 0.605 |
| HDL-C, mmol//L, mean ± SD | 1.04 ± 0.29 | 1.14 ± 0.37 | 1.10 ± 0.30 | 0.268 |
| Serum creatinine, μmol//L, mean ± SD | 63.26 ± 19.10 | 67.76 ± 28.84 | 73.60 ± 34.14 | 0.112 |
| Urinary microalbumin/creatinine ratio, mg/g, median (IQR) | 11.80 (7.15, 28.73) | 27.00 (8.40, 58.40) | 20.80 (9.33, 163.65) | 0.012 |
|
| ||||
| Insulin treatment, n (%) | 25 (29.8) | 6 (22.2) | 15 (37.5) | 0.402 |
| Hypoglycemic agents, n (%) | 48 (57.1) | 14 (51.9) | 20 (50.0) | 0.727 |
| Antihypertensive medication, n (%) | 30 (35.7) | 11 (40.7) | 17 (42.5) | 0.740 |
| Antiplatelet medication, n (%) | 15 (17.9) | 8 (29.6) | 6 (15.0) | 0.294 |
| Lipid-modifying medication, n (%) | 28 (33.3) | 11 (40.7) | 10 (25.0) | 0.389 |
|
| ||||
| CRAE, μm, mean ± SD meanSD | 109.15 ± 8.96 | 106.37 ± 6.70 | 105.32 ± 7.62 | 0.039 |
| CRVE, μm, mean ± SD | 191.58 ± 16.47 | 200.34 ± 9.63 | 207.15 ± 8.59 | <0.001 |
| AVR, mean ± SD | 0.57 ± 0.04 | 0.53 ± 0.04 | 0.51 ± 0.04 | <0.001 |
|
| <0.001 | |||
| Mild burden, n (%) | 62 (73.8) | 14 (51.9) | 10 (25.0) | |
| Moderate to severe burden, n (%) | 22 (26.2) | 13 (48.1) | 30 (75.0) |
DR, diabetic retinopathy; NDR, no diabetic retinopathy; SD, standard deviation; IQR, interquartile range; LDL, low-density lipoprotein; HDL, high-density lipoprotein; CRAE, Central Retinal Arterial Equivalent; CRVE, Central Retinal Venous Equivalent; AVR, arteriole-to-venule ratio; CSVD, cerebral small vessel disease.
*Indicates that the difference was statistically significant compared with the NDR group.
FIGURE 4Frequency and severity of cerebral small vessel disease (CSVD) in the 3 study groups. DR, diabetic retinopathy; NDR, no diabetic retinopathy.
Clinical characteristics of the study population based on the total MRI burden of CSVD.
| Variables | Mild burden ( | Moderate to severe burden ( | |
| Age, y; mean ± SD | 61.3 ± 8.7 | 67.4 ± 7.2 | <0.001 |
| Male, n (%) | 43 (50.0) | 31 (47.7) | 0.779 |
|
| |||
| Smoking, n (%) | 17 (19.8) | 23 (35.4) | 0.031 |
| Alcohol consumption, n (%) | 11 (12.8) | 18 (27.7) | 0.021 |
| Hypertension, n (%) | 44 (51.2) | 52 (80.0) | <0.001 |
| Duration of diabetes, years, median (IQR) | 10 (6, 17) | 12 (6.5, 20.5) | 0.113 |
| Previous stroke, n (%) | 7 (8.1) | 21 (32.3) | <0.001 |
| Coronary heart disease, n (%) | 4 (4.7) | 4 (6.2) | 0.726 |
| Carotid artery plaques, n (%) | 47 (54.7) | 52 (80.0) | 0.001 |
| Systolic BP, mmHg, mean ± SD | 133 ± 18 | 141 ± 21 | 0.008 |
| Diastolic BP, mmHg, mean ± SD | 77 ± 11 | 78 ± 10 | 0.741 |
| BMI, kg/m2, mean ± SD | 24.05 ± 3.12 | 23.90 ± 3.61 | 0.781 |
|
| |||
| Fasting glucose, mmol//L, median (IQR) | 7.78 (6.47, 9.89) | 9.37 (7.47, 12.77) | 0.005 |
| HbA1c, %, median (IQR) | 8.10 (7.0, 9.68) | 9.40 (8.05, 10.90) | <0.001 |
| Total cholesterol, mmol//L, mean ± SD | 4.47 ± 1.17 | 4.28 ± 1.30 | 0.350 |
| Triglycerides, mmol//L, mean ± SD | 1.83 ± 1.12 | 1.79 ± 1.25 | 0.846 |
| LDL-C, mmol//L, mean ± SD | 2.48 ± 0.75 | 2.36 ± 0.83 | 0.475 |
| HDL-C, mmol//L, mean ± SD | 1.11 ± 0.32 | 1.02 ± 0.28 | 0.086 |
| Serum creatinine, μmol//L, mean ± SD | 60.95 ± 19.46 | 74.54 ± 30.93 | 0.001 |
| Urinary microalbumin/creatinine ratio, mg/g, median (IQR) | 11.80 (6.60, 27.58) | 20.50 (9.10, 97.95) | <0.001 |
|
| |||
| DR | <0.001 | ||
| NDR, n (%) | 62 (72.1) | 22 (33.8) | |
| Mild DR, n (%) | 14 (16.3) | 13 (20.0) | |
| More than mild DR, n (%) | 10 (11.6) | 30 (46.2) | |
| CRAE, μm, mean ± SD | 109.45 ± 7.93 | 105.24 ± 8.42 | 0.002 |
| CRVE, μm, mean ± SD | 193.95 ± 13.54 | 201.67 ± 16.25 | 0.002 |
| AVR, mean ± SD | 0.57 ± 0.04 | 0.52 ± 0.05 | <0.001 |
DR, diabetic retinopathy; NDR, no diabetic retinopathy; SD, standard deviation; IQR, interquartile range; LDL, low-density lipoprotein; HDL, high-density lipoprotein; CRAE, Central Retinal Arterial Equivalent; CRVE, Central Retinal Venous Equivalent; AVR, arteriole-to-venule ratio; CSVD, cerebral small vessel disease.
Multivariate logistic regression analysis of the total MRI burden of CSVD.
| Variable | OR | 95% CI | |
| Age | 1.100 | 1.024∼1.181 | 0.009 |
| Hypertension | 3.531 | 1.118∼11.148 | 0.031 |
| HbA1c | 1.601 | 1.117∼2.294 | 0.010 |
| More than mild DR | 4.383 | 1.179∼17.202 | 0.028 |
| CRAE | 0.490 | 0.256∼0.936 | 0.031 |
| CRVE | 1.475 | 1.016∼2.143 | 0.041 |
OR, odds ratio; CI, confident interval; DR, diabetic retinopathy; CRAE, Central Retinal Arterial Equivalent; CRVE, Central Retinal Venous Equivalent; CSVD, cerebral small vessel disease.